CTC BIO

At a glance

CTC BIO filed 15 disclosures in the last 12 months.

Revenue for 2025 was ₩124B, up 3.2% on 2024. Operating margin was 5% against -4.2% a year earlier. Debt was 97% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩68.1B and operating profit of ₩8.4B.

The 2025 annual report lists 237 employees with an average tenure of 5.8 years and average pay of ₩46.8M, #1591 of 1,829 listed companies by average pay. Its 9 directors and auditors were paid ₩202.6M each on average. It paid no cash dividend for 2025. (주)바이오노트 and related parties held 31.74% at year end.

From the 2025 annual report

Staff: 237 (155 men, 82 women), of whom 3 on fixed-term contracts. Total pay for the year: ₩11.1B. Directors and auditors: 9, paid ₩1.8B in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)바이오노트 holds 23.04%; with 1 related party the group holds 31.74% of common shares at year end (from 21.14% at the start of the year).

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary